Therapeutic Evidence of Human Mesenchymal Stem Cell Transplantation for Cerebral Palsy: A Meta-Analysis of Randomized Controlled Trials
Table 2
GRADE summary of human mesenchymal stem cell transplantation for cerebral palsy.
Outcome
Absolute effect estimates (95% CI)
Relative effect (95% CI)
Participants (studies)
Evidence (GRADE)†
Comments
Control
hMSC therapy
GMFM
—
SMD 1.1 higher (0.66 to 1.53 higher)
—
163 (3)
⊕⊕⊕⊕ High
hMSC therapy has important benefit in increasing GMFM.
CFA
—
SMD 1.3 higher (0.71 to 1.90 higher)
—
96 (3)
⊕⊕⊕⊕ Moderate
hMSC therapy has important benefit in increasing CFA.
Upper respiratory infection
468 per 1000
417 per 1000 (267 to 651) Difference: 51 fewer per 1000 (201 to 183)
RR 0.89 (0.57 to 1.39)
93 (2)
⊕⊕⊕○ Moderate
hMSC therapy did not increase AE of upper respiratory infection.
Diarrhea
298 per 1000
241 per 1000 (125 to 468) Difference: 57 fewer per 1000 (173 to 170)
RR 0.81 (0.42 to 1.57)
93 (2)
⊕⊕⊕○ Moderate
hMSC therapy did not increase AE of diarrhea.
Constipation
106 per 1000
65 per 1000 (16 to 260) Difference: 41 fewer per 1000 (90 to 153)
RR 0.61 (0.15 to 2.44)
93 (2)
⊕⊕⊕○ Moderate
hMSC therapy did not increase AE of constipation.
†High: we are confident that the true effect of outcomes lies close to the estimate of the effect. Moderate: we are moderately confident that the assessed effects and the true effect are likely to be close to the assessed effects. CI: confidence interval; RR: risk ratio; AE: adverse event; SMD: standardized mean difference.
